Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €4.00 EUR
Change Today -0.098 / -2.39%
Volume 938.3K
As of 3:35 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

evotec ag (EVT) Snapshot

Open
€4.09
Previous Close
€4.10
Day High
€4.13
Day Low
€4.00
52 Week High
07/25/14 - €4.33
52 Week Low
10/16/14 - €2.42
Market Cap
527.2M
Average Volume 10 Days
1.1M
EPS TTM
€-0.03
Shares Outstanding
131.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EVOTEC AG (EVT)

Related News

No related news articles were found.

evotec ag (EVT) Related Businessweek News

No Related Businessweek News Found

evotec ag (EVT) Details

Evotec AG provides drug discovery solutions to the pharmaceutical, biotechnology, and academic sectors worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers a range of drug discovery services, such as anti-infectives, target identification and validation, hit identification, compound management, chemistry, ADME (absorption, distribution, metabolism, and excretion) profiling, proteomics, cell and protein production, in vitro pharmacology, in vivo pharmacology, and integrated services. The company has various products under clinical stage, including EVT302 that has completed Phase II clinical trials for the treatment of Alzheimer's disease; EVT201, which is in Phase II clinical trials for the treatment of insomnia; Somatoprim that is in Phase II clinical trials for the treatment of Acromegaly; EVT100, which has completed Phase I clinical trials for the treatment of CNS diseases; EVT401 that has completed Phase I clinical trials for the treatment of inflammation; and ND, a Phase I clinical trial product for the treatment of oncology. Its pre-clinical stage products include ND for pain and oncology, and EVT770 for diabetes type 2/1; and discovery stage products comprise various products for inflammation, diabetes type 2/1, kidney disease, oncology, Alzheimer’s disease, and CNS/MS. The company has alliances and partnerships with AstraZeneca AB, Bayer Pharma AG, CHDI Foundation, Inc., MedImmune, LLC/AstraZeneca PLC, Genentech, Inc., Jain Foundation Inc., Janssen Pharmaceuticals, Inc., Johnson & Johnson Innovation, Novartis AG, F. Hoffmann-La Roche AG, Shire plc, and UCB Pharma. It also has strategic collaboration with Fraunhofer Institute for Molecular Biology and Applied Ecology and Sanofi; and collaboration with Convergence Pharmaceuticals Holdings Ltd., Debiopharm Group, Eternygen GmbH, Medicines for Malaria Venture, and Second Genome, Inc. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.

727 Employees
Last Reported Date: 05/12/15
Founded in 1993

evotec ag (EVT) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: €459.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €323.0K
Chief Operating Officer and Member of Managem...
Total Annual Compensation: €361.0K
Chief Scientific Officer and Member of Manage...
Total Annual Compensation: €361.0K
Compensation as of Fiscal Year 2014.

evotec ag (EVT) Key Developments

Evotec Provides Revenue Guidance for the Fiscal 2015

Evotec provided revenue guidance for the fiscal 2015. The company raised its revenue target for 2015 due to the proceeds expected from an alliance with French Sanofi. Revenue excluding milestones, upfronts and licences is now expected to increase by more than 35% in 2015, compared with a rise of 20% expected earlier.

Evotec AG Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Evotec AG reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, revenues were €21,542,000 against €17,611,000 a year ago. This increase includes a favourable currency impact. Operating loss was €3,300,000 against €3,482,000 a year ago. LBITDA adjusted was €327,000 against €1,308,000 a year ago. Net result loss was €1,072,000 against €4,006,000 a year ago. Net loss per basic and diluted share was €0.01 against €0.03 a year ago.

Evotec AG Presents at BioEquity Europe 2015, May-19-2015 03:00 PM

Evotec AG Presents at BioEquity Europe 2015, May-19-2015 03:00 PM. Venue: InterContinental Vienna, Vienna, Austria.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVT:GR €4.00 EUR -0.098

EVT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $1.71 USD -0.03
Curis Inc $3.04 USD -0.06
Cytokinetics Inc $6.22 USD -0.05
Exelixis Inc $3.15 USD +0.01
Infinity Pharmaceuticals Inc $12.85 USD -0.02
View Industry Companies
 

Industry Analysis

EVT

Industry Average

Valuation EVT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.8x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOTEC AG, please visit www.evotec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.